Adaptive Biotechnologies
1551 Eastlake Ave E
Suite 200
Seattle
Washington
98102
United States
146 articles with Adaptive Biotechnologies
-
Adaptive Biotechnologies to Participate in Upcoming June 2022 Investor Conferences
5/26/2022
Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced it will be participating in the following investor conferences.
-
Adaptive Biotechnologies Reports First Quarter 2022 Financial Results
5/4/2022
Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported financial results for the quarter ended March 31, 2022.
-
Adaptive Biotechnologies to Present at the BofA Securities 2022 Healthcare Conference
5/2/2022
Adaptive Biotechnologies Corporation announced it will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada.
-
As Omicron dominates the COVID-19 landscape, scientists are urging the FDA to reconsider how the agency defines immune responses.
-
Shares of Adaptive are climbing this morning after the company announced a reorganization of priorities to spur future growth, including a workforce reduction of approximately 12%.
-
Adaptive Biotechnologies to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2/2/2022
Adaptive Biotechnologies Corporation announced it will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.
-
Updated: Adaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced it will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference.
-
Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Disease (MRD) Assay, clonoSEQ® for Blood Cancer Patients
11/11/2021
Adaptive Biotechnologies Corporation announced that Palmetto GBA’s Molecular Diagnostics Program has finalized a local coverage determination which supports the Medicare coverage for clonoSEQ® to detect and monitor minimal residual disease in patients with B-cell acute lymphoblastic leukemia, multiple myeloma and chronic lymphocytic leukemia.
-
Adaptive Biotechnologies Presents New Data During IDWeek Demonstrating the Capability of Its Immune Medicine Platform to Distinguish Between SARS-CoV-2 Infection and Vaccine Response and Detect Lyme Disease
10/2/2021
Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, is presenting new data from three studies demonstrating the potential clinical utility of T-cell testing using T-cell receptor repertoire characterization for infectious diseases during IDWeek 2021, which is being held virtually.
-
Adaptive Biotechnologies Announces Grand Opening of State-of-the-Art Headquarters and Expands Footprint in Seattle
9/21/2021
Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced the opening of its new corporate headquarters and laboratory facility located in the heart of South Lake Union – Seattle’s life sciences hub.
-
Adaptive Biotechnologies Reports Second Quarter 2021 Financial Results
8/4/2021
Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported financial results for the quarter ended June 30, 2021.
-
Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer
8/4/2021
Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced the appointment of Nitin Sood to the newly created position of chief commercial officer, effective immediately.
-
The T cell response was measured with immunoSEQ® T-MAP™ COVID, a clinical test developed by Adaptive Biotechnologies.
-
New Study Published in Nature Provides Further Evidence that COVID-19 Vaccine Induced T-Cell Response Targets Known SARS-CoV-2 Variants of Concern
6/9/2021
Adaptive’s immunoSEQ T-MAP COVID provides potential explanation for preservation of Johnson & Johnson vaccine (Ad26.COV2.S) response to variants even when neutralizing antibodies are diminished
-
Adaptive Biotechnologies Reports First Quarter 2021 Financial Results
5/5/2021
Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported financial results for the quarter ended March 31, 2021.
-
Adaptive Biotechnologies to Present at the BofA Securities 2021 Virtual Healthcare Conference
4/27/2021
Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced it will be participating in the upcoming BofA Securities 2021 Virtual Healthcare Conference.
-
Adaptive Biotechnologies to Present at the Cowen 41st Annual Healthcare Conference
2/25/2021
Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced it will be participating in the upcoming Cowen 41st Annual Healthcare Conference.
-
Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Teams With Adaptive Biotechnologies to Market immunoSEQ® Assay, the Leading Quantitative Large-Scale Immunosequencing Solution
12/21/2020
Q 2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Teams With Adaptive Biotechnologies to Market immunoSEQ® Assay, the Leading Quantitative Large-Scale Immunosequencing Solution MORRISVILLE, N.C.--( BUSINESS WIRE )-- Q 2 Solutions, a leading global clinical trial laboratory services organization, resulting from an IQVIA and Quest Diagnostics joint venture, today announced a partnership with Adaptive Biotechnologies, a pioneer and leader in im
-
Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting
12/6/2020
MRD assessment with clonoSEQ improves outcomes both for patients and the healthcare system, as patients with undetectable MRD may be able to discontinue active treatment
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.